Grovel Drugs And Chemicals Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 9.50 M
as on 09-07-2024
- Paid Up Capital ₹ 9.30 M
as on 09-07-2024
- Company Age 29 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 19.93 M
as on 09-07-2024
- Revenue 0.92%
(FY 2020)
- Profit -9.03%
(FY 2020)
- Ebitda 21.51%
(FY 2020)
- Net Worth 3.09%
(FY 2020)
- Total Assets 1.49%
(FY 2020)
About Grovel Drugs And Chemicals
The Company is engaged in the Chemicals And Resources Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 9.50 M and a paid-up capital of Rs 9.30 M.
The company currently has active open charges totaling ₹1.99 Cr.
Yugandhar Sabbineni and Maniprabha Sabbineni serve as directors at the Company.
- CIN/LLPIN
U24230TG1995PTC020587
- Company No.
020587
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jun 1995
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Medak, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Grovel Drugs And Chemicals Private Limited offer?
Grovel Drugs And Chemicals Private Limited offers a wide range of products and services, including Ayurvedic Herbal Syrups & Tonics, Ayurvedic Brain Tonic, Hair Shampoo, Aloe Vera Shampoo, Ayurvedic Joint Pain Relief Oil, Ortho Rich Pain Relief Oil, Ayurvedic Churna and Goli, Ayurvedic Cosmetics, Ayurvedic Hair Oil, Herbal Soaps.
Who are the key members and board of directors at Grovel Drugs And Chemicals?
Executive Team (1)
YS
Yugandhar Sabbineni
Managing DirectorAppointment Date: 29-Nov-1999
Status: Current
Board Members(1)
Financial Performance and Corporate Structure Insights of Grovel Drugs And Chemicals.
Grovel Drugs And Chemicals Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 0.92% increase. The company also saw a slight decrease in profitability, with a 9.03% decrease in profit. The company's net worth moved up by a moderate rise of 3.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Grovel Drugs And Chemicals?
In 2020, Grovel Drugs And Chemicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 25 Mar 2021 | ₹7.50 M | Open |
Citicorp Finance (India) Ltd. Creation Date: 16 Nov 2004 | ₹0.43 M | Open |
State Bank Of Hyderabad Creation Date: 22 Jun 2004 | ₹3.00 M | Open |
How Many Employees Work at Grovel Drugs And Chemicals?
Unlock and access historical data on people associated with Grovel Drugs And Chemicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Mar 12, 2015, Grovel Drugs And Chemicals has raised a total of ₹ 6.8 M, with the most recent deal valued at ₹ 6.8 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
